---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005787"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:13:58.565249+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience appoints Stephen DeNelsky to board, effective Sept 5, 2025

## Summary
- Stephen DeNelsky, Managing Director at Oaktree Capital Management, appointed to Board and Nominating & Governance Committee.
- He has 30 years of healthcare equity research/valuation experience across life sciences, pharma, devices.
- Compensation includes 110,000 RSUs and $91,000 annual cash retainer (total ~$135,000) for non-employee director.
- DeNelsky also serves on board of Visioncare Inc and previously on Integrated Diagnostics and AMICAS.
- No arrangement for his selection as director and no family relationships with other directors/officers.

## SEC filing metadata
- accession: 0001171843-25-005787
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325005787/0001171843-25-005787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325005787/f8k_090925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005787
- JSON: https://secwatch.observer/filing/0001171843-25-005787.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.